Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2022-11-21 00:00:00 ET · period of report 2022-11-17 · accession 0001104659-22-120780 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2022-11-21 | 2022-11-17 | ACRV | RA Capital Healthcare Fund LP | Dir, 10% | C - Cnv Deriv | — | +1.42M | 994.7K | New | — |
| DI | 2022-11-21 | 2022-11-17 | ACRV | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $12.50 | +3.39M | 4.38M | +341% | +$42.37M |
| DMI | 2022-11-21 | 2022-11-17 | ACRV | RA Capital Healthcare Fund LP | Dir, 10% | C - Cnv Deriv | $0.00 | -3.50M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-17 | C | A | 426,302 | — | 426,302 | I See Footnotes | — | — | (F1) On November 17, 2022 each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-2.466 upon closing of the initial public offering of the Issuer's common stock without payment of further consideration. The shares had no expiration date. (F3) These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| 2 | Common | Common Stock | 2022-11-17 | P | A | 3,389,500 | $12.50 | 4,384,206 | I See Footnotes | — | — | (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| 3 | Common | Common Stock | 2022-11-17 | C | A | 994,706 | — | 994,706 | I See Footnotes | — | — | (F1) On November 17, 2022 each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-2.466 upon closing of the initial public offering of the Issuer's common stock without payment of further consideration. The shares had no expiration date. (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| 4 | Derivative | Series B Preferred Stock | 2022-11-17 | C | D | 2,452,947 | $0.00 | 0 | I See footnotes | — · — to — | 994,706 Common Stock | (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F1) On November 17, 2022 each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-2.466 upon closing of the initial public offering of the Issuer's common stock without payment of further consideration. The shares had no expiration date. |
| 5 | Derivative | Series B Preferred Stock | 2022-11-17 | C | D | 1,051,263 | $0.00 | 0 | I See footnotes | — · — to — | 426,302 Common Stock | (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F3) These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). (F1) On November 17, 2022 each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-2.466 upon closing of the initial public offering of the Issuer's common stock without payment of further consideration. The shares had no expiration date. |